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AbsTrACT
background Mycoplasma genitalium is a common 
cause of non-gonococcal non-chlamydial urethritis 
and cervicitis. testing of asymptomatic populations 
has been proposed, but prevalence in asymptomatic 
populations is not well established. We aimed to 
estimate the prevalence of M. genitalium in the 
general population, pregnant women, men who have 
sex with men (MSM), commercial sex workers (cSWs) 
and clinic-based samples,
Methods We searched embase, Medline, indMeD, 
african index Medicus and lilacS from 1 January 
1991 to 12 July 2016 without language restrictions. 
We included studies with 500 participants or more. 
two reviewers independently screened and selected 
studies and extracted data. We examined forest plots 
and conducted random-effects meta-analysis to estimate 
prevalence, if appropriate. Between-study heterogeneity 
was examined using the i2 statistic and meta-regression.
results Of 3316 screened records, 63 were included. in 
randomly selected samples from the general population, 
the summary prevalence was 1.3% (95% ci 1.0% to 
1.8%, i2 41.5%, three studies, 9091 people) in countries 
with higher levels of development and 3.9% (95% ci 2.2 
to 6.7, i2 89.2%, three studies, 3809 people) in countries 
with lower levels. Prevalence was similar in women 
and men (P=0.47). in clinic based samples, prevalence 
estimates were higher, except in asymptomatic patients 
(0.8%, 95% ci 0.4 to 1.4, i2 0.0%, three studies, 2889 
people). Summary prevalence estimates were, in the 
following groups: pregnant women 0.9% (95% ci 
0.6% to 1.4%, i2 0%, four studies, 3472 people), MSM 
in the community 3.2% (95% ci 2.1 to 5.1, i2 78.3%, 
five studies, 3012 people) and female cSWs in the 
community 15.9% (95% ci 13.5 to 18.9, i2 79.9%, four 
studies, 4006 people).
Discussion this systematic review can inform testing 
guidelines for M. genitalium. the low estimated 
prevalence of M. genitalium in the general population, 
pregnant women and asymptomatic attenders at 
clinics does not support expansion of testing to these 
groups.
registration numbers PrOSPerO: crD42015020420
InTroDuCTIon
Mycoplasma genitalium is a cause of non-gonococcal 
non-chlamydial urethritis in men and cervicitis in 
women,1-3 and is reported to be associated with 
pelvic inflammatory disease, infertility and preterm 
birth.4 M. genitalium was first isolated in the early 
1980s in men with non-gonococcal urethritis5 but, 
owing to difficulties in detecting the microorganism 
by culture, most research on M. genitalium has been 
done since the development of nucleic acid ampli-
fication tests (NAATs) in the early 1990s.1 In popu-
lations studied in healthcare settings, M. genitalium 
has been detected in substantial proportions of men 
with urethritis and women with cervicitis.1 2 Based 
on these studies, routine testing has been suggested 
to detect and treat M. genitalium in asymptomatic 
attenders in healthcare settings6 and the recommen-
dation has also been extended to low risk general 
populations.7 Multiplex NAATs are being used 
increasingly to detect multiple sexually transmitted 
pathogens,8 9 increasing pressure for their routine 
use in asymptomatic populations.
Criteria for assessing the appropriateness of 
screening for a disease in the population include 
requirements that the disease is an important 
public health problem and that screening has 
been shown to do more good than harm.10 Precise 
estimates of the prevalence of M. genitalium in 
asymptomatic people in the general population 
are needed to assess public health importance 
and as input data for mathematical modelling 
studies that can investigate the potential effects 
of screening interventions on STI prevalence.11 
The population prevalence of M. genitalium has 
not been ascertained systematically, to our knowl-
edge. Non-systematic reviews have reported 
prevalence estimates ranging from 0.7% to 3.3% 
in the general population1 and from zero to 
20% in a range of female study populations 
described as ‘low risk’.12 The frequency of M. 
genitalium infection is also of interest in specific 
populations whose behaviour places them at high 
risk of STI, such as men who have sex with men 
(MSM) and commercial sex workers (CSWs) 
and pregnant women, in whom transmission of 
infection to a fetus might have adverse conse-
quences. The primary objective of this system-
atic review was to estimate the prevalence of M. 
genitalium in the general population. Secondary 
objectives were to estimate M. genitalium preva-
lence in specific groups: MSM, CSWs, pregnant 
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METhoDs
We followed a predefined review protocol.13 This report pres-
ents the findings of the first of three review questions (preva-
lence of M. genitalium). Two other review questions (incidence 
and persistence of untreated M. genitalium infection) will be 
addressed in a separate report. We report the findings using 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA, research checklist online).14
Eligibility criteria
We included studies that provided an estimate of the preva-
lence of M. genitalium infection in urogenital or rectal samples 
from women and men older than 13 years in any country 
from 1991 onwards, when the first NAAT was described.1 
We included studies conducted among people in the general 
population or among attenders at healthcare settings that used 
NAAT to detect M. genitalium. Eligible study designs were 
cross-sectional studies and baseline data in cohort studies and 
randomised controlled trials, published as full papers, abstracts 
or conference posters. We excluded laboratory studies, studies 
restricted to people with a specific condition, for example, 
men with urethritis, women with abnormal cervical smears 
and women with pregnancy complications. Studies need to 
be large enough to estimate prevalence with sufficient preci-
sion.15 Studies with small sample sizes result in imprecise esti-
mates that tend to be of lower methodological quality than 
large studies.16 We decided by consensus that we wanted to 
include at least 20 studies in the review. After assessing the 
sample sizes reported in the abstracts of identified records, we 
determined that inclusion of studies with 500 participants or 
more would result in at least 20 studies in the review.
Information sources and search strategy
We searched Medline, Embase, African Index Medicus, 
IndMED and LILACS databases from 1 January 1991 to 
12 July 2016 without language restrictions. The full search 
strategy for Medline and Embase is provided in  online supple-
mentary text S1. The other databases were searched using 
only the term ‘Mycoplasma genitalium’. We used Endnote 
(V.7; Thomson Reuters) to import, de-duplicate and manage 
retrieved records.
study selection
Two reviewers (LB, MC) independently screened the identified 
records using prepiloted checklists to assess eligibility, first of 
abstracts and titles and then of full text records. Differences 
were resolved by discussion or adjudication by a third reviewer 
(NL). When multiple records reported on the same study popu-
lation, we defined a primary record to represent the study, based 
on a combination of the following factors: description as a main 
paper by the authors, most detailed report of methods, preva-
lence reported as the main result and date of publication.
Data extraction
Two researchers extracted data independently (LB, DE-G, HA, 
G-RL, MC) for every included study, using a piloted extraction 
form in an online database (Research Electronic Data Capture, 
REDCap, Vanderbilt University, Tennessee). We resolved differ-
ences by discussion. The data extraction form included items 
about study design, demographic characteristics, sample size, 
methods of participant selection and specimen collection, 
response rates, number of infected participants and number 
tested and reported prevalence estimates (with 95% CIs) overall 
and for prespecified subgroups. If samples were taken from more 
than one anatomical site, we used the value for the site with the 
highest proportion of positive tests.
We also recorded a measure of the level of development of the 
country in which the study was done using the Human Devel-
opment Index (HDI) 2015 dataset,17 which we categorised as 
higher (combining very high and high) or lower (medium and 
low). We defined studies a priori as ‘general population’ if they 
used any method to draw a random sample from the popula-
tion of a whole country or a region, or as ‘community based’ if 
participants were enrolled outside healthcare settings but used 
non-random methods such as convenience sampling, snowball 
or respondent-driven sampling. Studies conducted in health-
care settings were coded according to their study population: 
clinic attenders, pregnant women, MSM and female CSWs. 
Studies that had enrolled participants from both healthcare 
settings and the community and did not stratify results were 
coded as clinic-based studies. We labelled studies according 
to the country in which the fieldwork was done and use these 
as study names in the text, tables and figures (online supple-
mentary table S1). If there was more than one study from the 
same country, we assigned numbers after the country name. 
We generated separate strata within studies if they included 
participants from more than one country or from more than 
one relevant population subgroup, for example, MSM and 
heterosexual adults.
risk of bias in individual studies
To evaluate the individual studies, we adapted an instru-
ment from another systematic review of studies of Chlamydia 
trachomatis prevalence (online supplementary text S2).18 Two 
reviewers independently assessed each item as being at high, low 
or uncertain risk of bias. Differences were resolved by discussion.
summary measure and synthesis of results
The outcome was the estimated prevalence (and 95% CI), defined 
as the number of specimens with a positive M. genitalium test 
result divided by the number of eligible participants with a valid 
test result. Where possible, we confirmed the published values 
using raw numbers reported in the publication. In studies that 
reported weighted prevalence estimates and CIs or where raw 
numbers were not available, we used the information reported 
by the authors. We calculated survey response rates, whenever 
possible, by dividing the number of participants tested by the 
number of eligible people asked to participate.
We initially examined the estimates of M. genitalium preva-
lence visually in forest plots. We stratified studies, based on a 
previous study showing factors that contribute to heterogeneity 
in estimates of C. trachomatis prevalence,18 by sampling method 
(random sample of the general population, community based 
or clinic based), study population (general population, preg-
nant women, MSM, CSW), HDI (higher or lower) and, where 
reported, by sex and age of participants as under 25 years or 
25 years and older.
We used the I2 statistic to assess heterogeneity that was not due 
to random variation.19 Heterogeneity was considered moderate 
or high when I2 was greater than 50% or 75%, respectively. We 
used random effects meta-analysis to combine prevalence esti-
mates where appropriate, assuming that, even when results were 
stratified, there might be real differences in M. genitalium prev-
alence between studies. We log-transformed the prevalence esti-
mates and 95% CI before meta-analysis and back-transformed 
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scale. We did not conduct meta-analysis on the logit scale because 
the log odds and CIs could not be obtained from studies that 
reported weighted prevalence estimates. We did a meta-regres-
sion analysis to examine possible factors (HDI, use of probability 
sampling, sample size, response rate, sex and use of adequate 
sample and target populations) contributing to heterogeneity in 
general population and clinic based studies. Analyses were done 
using the ‘metan’ and ‘metareg’ commands in Stata (Stata V.13; 
Stata, Austin, Texas, USA).
rEsulTs
search results
We screened the titles and abstracts of 3316 unique records 
published after 1991 and the full text of 833 studies 
(online supplementary figure S1). A total of 63 records were 
included with participants who were sampled at random from 
the general population20–25 or using alternative community based 
methods,26–30 MSM and male-to-female transgendered,31–36 
female CSWs37–41 and pregnant women.42–45 Of these, 37 
studies included patients attending healthcare settings.8 46–81 
We report results using the country name and number of the 
study or subgroup within a study. We did not include any studies 
conducted in male sex workers.
Table 1 shows that most characteristics of included studies 
were similar to those of studies excluded because the sample size 
was below 500 (details in online supplementary data). The distri-
bution of included and excluded studies was broadly similar. 
Eight of the excluded studies included participants from the 
community, but all studies that used probability based sampling 
methods were included.
risk of bias in individual studies
No study was at low risk of bias in all domains (online supple-
mentary figure S2). The studies at lowest risk of bias were those 
that used probability sampling in the general population. Only 
one study compared responders and non-responders and that 
study found differences between these groups.25 Reporting of 
complete results, including CIs and baseline data, was consid-
ered adequate in 22 studies.
studies in the general population and community
We included 11 studies, 6 of which were in countries with higher 
HDI (Denmark 1,24 Great Britain 2 and Great Britain 4,25 26 
Norway 4,27 Russian Federation 328 and USA 2,20 n=13 331) 
and five in countries with a lower (Honduras 1,21 Vietnam 
1,22 Kenya 1,29 Madagascar 1,30 Tanzania 1,23 n=4978) HDI 
(figure 1, online supplementary table S2).
The summary average general population prevalence of M. geni-
talium in three studies in countries with higher HDI was 1.3% 
(95% CI 1.0% to 1.8%, I2 41.5%, n=9091, figure 1), with low 
between-study heterogeneity in three studies (one region in Denmark 
124 or the whole population in Great Britain 4 and USA 2).20 25 
In three studies in higher HDI countries that enrolled participants 
using convenience sampling methods from subnational communi-
ties (n=4240, online supplementary table S2), between study heter-
ogeneity was higher than in the studies that used random sampling 
methods, but the summary average prevalence was similar (1.6%, 
95% 0.8% to 3.4%, I2 77.0%).26–28 There were too few estimates 
from adults aged 25 years and over to compare M. genitalium prev-
alence between age groups. Among adults under 25 years, average 
M. genitalium prevalence was 1.7% (95% CI 1.0% to 2.6%, 
I2 80.3%) in women and 0.3% in men (0.1% to 1.4%, I2 91.3%) 
(online supplementary figure S3).
The surveys from five countries with lower HDI enrolled 
very different populations and M. genitalium prevalence esti-
mates were more variable (figure 1, online supplementary table 
S2).21–23 29 30 The summary estimate of prevalence in three studies 
that used probability sampling was 3.9% (2.2 to 6.7, I2 89.2%) 
and, in two studies that used other methods to enrol participants 
from community settings, 5.2% (2.4 to 11.5, I2 86.8%).
In a meta-regression analysis that compared characteristics of 
all studies in adults in the general population, there was some 
statistical evidence to suggest higher estimates of M. genitalium 
prevalence in countries with lower than higher HDI (differ-
ence 3.1%, 95% CI −0.1% to 6.3%, P=0.057) but no statis-
tical evidence of a difference by sex (0.9%, 95% CI −1.6% to 
3.3% P=0.47) or for other study related variables that were 
examined (online supplementary table S3).
Table 1 Characteristics of included and excluded studies
Characteristic
Included records Excluded records
n=63* (%) n=113 (%)
Population
  General population 6 9.5 0 0.0
  Community 5 7.9 8 7.1
  Clinic based or mixed 37 58.7 65 57.5
  Female commercial sex workers 5 7.9 11 9.7
  Men who have sex with men 8 12.7 6 5.3
  Pregnant women 4 6.3 9 8.0
  Other 0 0.0 6 5.3
  Unclear/not reported 0 0.0 8 7.1
Human Development Index of country
  Very high 44 69.8 65 57.5
  High 6 9.5 25 22.1
  Medium 7 11.1 7 6.2
  Low 5 7.9 9 8.0
  Multiple countries 1 1.6 2 1.8
  Unclear 0 0.0 5 4.4
Sex 0.0 0.0
  Women and men 25 39.7 18 15.9
  Women only 23 36.5 61 54.0
  Men only 15 23.8 33 29.2
  Unclear 0 0.0 1 0.9
Sample size
  <500 0 0.0 113 100.0
  500–1000 37 58.7 NA   NA
  1001–2000 13 20.6 NA   NA
  2001–3000 4 6.3 NA   NA
  3001–4000 2 3.2 NA   NA
  4001–5000 2 3.2 NA   NA
  5001–10 000 4 6.3 NA   NA
  >10 000 1 1.6 NA   NA
Publication year
  Before 2000 0 0.0 8 7.1
  2001–2004 5 7.9 2 1.8
  2005–2008 13 20.6 17 15.0
  2009–2012 23 36.5 34 30.1
  2013–2016 22 34.9 52 46.0
Percent positive tests
  Median %, (range) 8.1 (0.3–26.3) 8.0 (0.0–63.4)
*Three records report on more than one study population: Netherlands 1 and 





ber 2018 by guest. Protected by copyright.
http://sti.bmj.com/
Sex Transm
 Infect: first published as 10.1136/sextrans-2017-053384 on 9 February 2018. Downloaded from
 
257Baumann L, et al. Sex Transm Infect 2018;94:254–261. doi:10.1136/sextrans-2017-053384
Epidemiology
Pregnant women in antenatal clinics and women in the 
general population
We included four studies in pregnant women before 14 weeks’ 
gestation, all in countries with higher HDI (n=3472, age 
range 16 to 48 years; France 2,45 Great Britain 1,42 Japan 143 
and USA 544; figure 2, online supplementary table S3) (0.9%, 
95% CI 0.6% to 1.4%, I2 0%). The estimated prevalence was 
slightly lower than in the three studies in women in the general 
population (1.4%, 95% CI 0.8% to 2.4%, I2 73.4%) but CI 
overlapped.
MsM and female CsW in community based and clinic based 
studies
Five studies from four records enrolled MSM from the commu-
nity (figure 3, online supplementary table S4) in specific areas 
in Australia 2,31 El Salvador 1,32 Guatemala 1 and Honduras 
3,33 and Nicaragua 1,34 (n=3012). The summary average 
prevalence in these studies was 3.2% (95% CI 2.1% to 5.1%, 
I2 78.3%) with moderate between study heterogeneity. The 
summary average estimate of M. genitalium prevalence in 
MSM enrolled from clinics in Germany 3,56 the Netherlands 
2,55 Norway 536 and USA 335 was 3.7% (95% CI 2.4% to 
5.6%, I2 78.5%).
Four studies enrolled female CSW in the community based 
studies in specific areas in southwest China 2,37 northern 
Germany 1,38 Honduras 239 and Uganda 1.40 Estimated M. 
genitalium prevalence was 15.9% (95% CI 13.5% to 18.9%, 
I2 79.9%, n=4006), which was lower than in one study 
that enrolled women from a clinic in Benin and Ghana 1.41
Clinic based studies
We included 37 studies from 14 countries, of which 24 were 
from Australia, Great Britain, Norway, South Korea and Sweden 
(online supplementary table S5 and figure S4). Estimates of M. 
genitalium were very heterogeneous (I2>95%), except for in 
three studies that only included patients without symptoms8 51 65 
Figure 1 Estimated prevalence of Mycoplasma genitalium in randomly selected samples of the general population or in other community-based 
samples, by Human Development Index (HDI). Solid diamond and lines show the point estimate and 95% CIs for each study. The diamond shows the 
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(0.8%, 95% CI 0.4% to 1.4%, I2 0%, n=2889). Most study popu-
lations included patients both with and without symptoms. Point 
estimates varied widely, both in studies that enrolled patients 
consecutively (range 1.0%52 to 8.7%,64 I2 96.1%) and studies in 
which the enrolment procedure was not clearly described (range 
0.6%79 to 12.6%,62 I2 98.2%), and we did not combine results. 
There was no consistent difference in prevalence estimates from 
specialist STI clinics and general practice or primary healthcare 
clinics (online supplementary figure S4 and table S5).
DIsCussIon
Main findings
In large nationally representative surveys conducted in very 
highly developed countries, the summary average preva-
lence estimate of M. genitalium was 1.3% (95% CI 1.0% to 
1.8%, three studies, I2 41.5%) in adults aged 16 to 44 years 
with no statistical evidence of a difference between men and 
women (P=0.47). Summary prevalence estimates were, in the 
following specific subpopulations: pregnant women 0.9% (0.6 
to 1.4%), MSM in community samples 3.2% (2.1 to 5.1%, five 
studies, I2 78.3%) and MSM in clinic based samples 3.7% (2.4 
to 5.6%, four studies, I2 78.5%). Prevalence estimates were 
higher in FSW, ranging from 13.2% in one community based 
study to 26.3% in one clinic based study. In clinic based 
surveys, prevalence estimates varied widely from 0.6% to 
12.6% and were not combined.
strengths and limitations
The broad search strategy is a strength of this review. It allowed 
for identification of a wide range of different studies, and it is 
unlikely that we missed large studies. The a priori defined inclu-
sion criteria allowed a clear selection process for the detected 
studies and duplicate screening and data extraction prevented 
data entry errors. By including only studies with 500 participants 
or more, we aimed to reduce the influence of small study biases 
that can distort results. This strategy included all studies that 
used methods to select random samples of the general popu-
lation and provided summary estimates with little heteroge-
neity for general population samples in very highly developed 
countries, pregnant women and asymptomatic people attending 
outpatient healthcare settings. Although we explored between-
study heterogeneity using meta-regression analysis, we did not 
identify factors that could explain a substantial proportion of 
the heterogeneity. Finally, we could not assess an earlier finding, 
in surveys of chlamydia prevalence,18 that lower response rates 
are associated with higher prevalence estimate because very 
few studies reported these results. Among studies that reported 
response rates, we did not find an association with M. genitalium 
prevalence (online supplementary table S3).
Interpretation and comparison with other studies
To our knowledge, this is the first systematic review assessing 
the prevalence of M. genitalium in different population groups, 
including those outside healthcare settings. Our findings suggest 
that M. genitalium might be less prevalent than C. trachomatis in 
the general population, but comparison is not straightforward. 
In a systematic review of population based surveys of C. tracho-
matis, estimated prevalence in adults <27 years in high-income 
countries was 4.3% (95% CI 3.6% to 5.0%, I2 0%) in women 
and 3.6% (95% CI 2.8% to 4.4%, I2 6.2%) in men,18 compared 
with our summary estimates of less than 2% for M. genitalium 
in women and men <25 years old. Within studies that tested for 
both pathogens, prevalence estimates for M. genitalium and C. 
trachomatis were similar in Great Britain,25 but higher for C. 
trachomatis than M. genitalium in Denmark24 and the USA.20 
It is, however, possible that M. genitalium prevalence has been 
Figure 2 Estimated prevalence of Mycoplasma genitalium in pregnant women in antenatal clinics and in randomly selected samples of women in 
the general population. Solid diamond and lines show the point estimate and 95% CIs for each study. The diamond shows the point estimate and 
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underestimated because the sensitivity of NAATs is lower than 
previously believed.9 In general, age differences seem less 
marked among women for M. genitalium than for C. tracho-
matis, where prevalence after age 25 years is much lower than 
in younger women. Age specific patterns of M. genitalium were, 
however, difficult to discern with certainty, largely because 
population-based studies that provided age-stratified estimates 
used non-comparable age groups and only two had estimates for 
participants older than 25 years.25 27
In clinic based surveys, participant selection methods and 
characteristics differed substantially between different types of 
clinics and countries. M. genitalium prevalence estimates were 
consistent and comparable (or even lower) than in general popu-
lation based surveys in studies that only enrolled asymptomatic 
patients or pregnant women in antenatal clinics. Among MSM, 
estimated M. genitalium prevalence was similar in commu-
nity based and clinic based studies.
Implications for clinical practice, policy and research
This systematic review provides evidence about the prevalence 
of M. genitalium that can be used in mathematical modelling 
studies to investigate the potential impact of screening inter-
ventions82 and to inform testing guidelines for infection.83 The 
trend for molecular diagnostic tests to include targets that iden-
tify multiple sexually transmitted pathogens means that testing 
for asymptomatic M. genitalium infection will become more 
widespread. High levels of antimicrobial resistance in M. geni-
talium are already a concern,84 so estimates of prevalence are 
also needed for monitoring purposes if drug resistance promotes 
further spread of infections. The absence of randomised 
controlled trials that demonstrate a clinical benefit of screening 
and the increasing prevalence of resistance to azithromycin are 
reasons for restricting widespread testing for M. genitalium.85 
The low estimated prevalence of M. genitalium in the general 
population, in pregnant women and in asymptomatic attenders 
in healthcare settings and absence of a clearly defined age group 
at higher risk of infection do not provide strong support for the 
appropriateness of universal or age based screening programmes 
for M. genitalium in these population groups.
Figure 3 Estimated prevalence of Mycoplasma genitalium in community based and clinic based samples of men who have sex with men and 
female sex workers. CSW, commercial sex worker; MSM, men who have sex with men; NR, not reported. Solid diamond and lines show the point 
estimate and 95% CIs for each study. The diamond shows the point estimate and 95% CIs of the summary estimate. The prevalence estimates are 
plotted on a logarithmic scale.
Key messages
 ► Routine screening for Mycoplasma genitalium infection has been 
proposed, but prevalence rates are not well established.
 ► In samples from the general population, the summary 
prevalence estimate is 1.3% in countries with higher 
development and 3.9% in countries with lower development.
 ► M. genitalium prevalence in the general population and 
differences in prevalence by age appear to be less than for 
Chlamydia trachomatis.
 ► The low prevalence estimates in the general population, 
pregnant women and asymptomatic clinic based patients do 




ber 2018 by guest. Protected by copyright.
http://sti.bmj.com/
Sex Transm
 Infect: first published as 10.1136/sextrans-2017-053384 on 9 February 2018. Downloaded from
 
260 Baumann L, et al. Sex Transm Infect 2018;94:254–261. doi:10.1136/sextrans-2017-053384
Epidemiology
Correction notice the paper has been corrected since it was published Online 
First. an error at the production stage meant the references were not in the correct 
order. We have since amended them and would like to apologise to the authors for 
this error.
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